Deerfield Management ANAB Position
Exited8-Fund ConvergenceDeerfield Management exited their position in AnaptysBio Inc. (ANAB) in Q3 2023, after holding the stock for 3 quarters.
The position was first reported in Q1 2023 and has been tracked across 3 quarterly 13F filings.
ANAB is a convergence signal: 8 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 30.6% of float with 9.8 days to cover, indicating significant bearish positioning against the stock.
About AnaptysBio Inc.
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Full company profile →Short Interest
30.6%
9.8 days to cover
Deerfield Management ANAB Position History
Frequently Asked Questions
Does Deerfield Management own ANAB?
No. Deerfield Management exited their position in AnaptysBio Inc. (ANAB) in Q3 2023. They previously held the stock for 3 quarters.
How many hedge funds own ANAB?
8 specialist biotech hedge funds currently hold ANAB, including EcoR1 Capital, Tang Capital Management, Deep Track Capital and 5 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deerfield Management first buy ANAB?
Deerfield Management's position in ANAB was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deerfield Management's ANAB position increasing or decreasing?
Deerfield Management completely exited their ANAB position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ANABCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deerfield ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →